Dental health in patients with and without HPV-positive oropharyngeal and tongue cancer.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 31 03 2022
accepted: 02 09 2022
entrez: 22 9 2022
pubmed: 23 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

Human papilloma virus is associated with oral and oropharyngeal cancer. Our aim was to examine oral health in patients with oropharyngeal (OPSCC) and oral tongue cancer (OTSCC), expecting better oral health among OPSCC patients. Fifty-five OPSCC patients with known HPV status and 59 OTSCC patients were randomly selected from a list of consecutive patients of the Helsinki University Hospital, Finland. Oral health was assessed from panoramic jaw radiographs. Total Dental Index (TDI) summarizing the dental health status was calculated and Finnish population study data were used for comparison. Descriptive statistics were used for analyses. Patients with HPV-positive OPSCC had higher periapical lesion index compared with HPV-negative OPSCC patients or with OTSCC patients. Residual roots were more common among OPSCC patients compared with OTSCC patients, because of their higher occurrence among HPV-negative OPSCC patients compared with OTSCC patients. Similarly, modified TDI score was significantly higher among OPSCC patients than among OTSCC patients, because of higher TDI score among HPV-negative OPSCC patients compared with OTSCC patients. OPSCC patients more often used a removable prosthesis than OTSCC patients. Dental health of the cancer patients was poorer when compared with the population data. Our study hypothesis was only partly confirmed. Periapical lesions were more prevalent among HPV-positive OPSCC patients, compared with the other groups. The number of residual roots was higher among HPV-negative subgroup. Thus, OPSCC patients had worse oral health parameters than OTSCC patients.

Sections du résumé

BACKGROUND
Human papilloma virus is associated with oral and oropharyngeal cancer. Our aim was to examine oral health in patients with oropharyngeal (OPSCC) and oral tongue cancer (OTSCC), expecting better oral health among OPSCC patients.
MATERIAL AND METHODS
Fifty-five OPSCC patients with known HPV status and 59 OTSCC patients were randomly selected from a list of consecutive patients of the Helsinki University Hospital, Finland. Oral health was assessed from panoramic jaw radiographs. Total Dental Index (TDI) summarizing the dental health status was calculated and Finnish population study data were used for comparison. Descriptive statistics were used for analyses.
RESULTS
Patients with HPV-positive OPSCC had higher periapical lesion index compared with HPV-negative OPSCC patients or with OTSCC patients. Residual roots were more common among OPSCC patients compared with OTSCC patients, because of their higher occurrence among HPV-negative OPSCC patients compared with OTSCC patients. Similarly, modified TDI score was significantly higher among OPSCC patients than among OTSCC patients, because of higher TDI score among HPV-negative OPSCC patients compared with OTSCC patients. OPSCC patients more often used a removable prosthesis than OTSCC patients. Dental health of the cancer patients was poorer when compared with the population data.
CONCLUSIONS
Our study hypothesis was only partly confirmed. Periapical lesions were more prevalent among HPV-positive OPSCC patients, compared with the other groups. The number of residual roots was higher among HPV-negative subgroup. Thus, OPSCC patients had worse oral health parameters than OTSCC patients.

Identifiants

pubmed: 36137133
doi: 10.1371/journal.pone.0274813
pii: PONE-D-22-09474
pmc: PMC9499192
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0274813

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

BMJ. 1989 Mar 25;298(6676):779-81
pubmed: 2496855
Oral Oncol. 2014 May;50(5):370-9
pubmed: 24331868
JAMA Otolaryngol Head Neck Surg. 2013 Oct;139(10):1054-60
pubmed: 24030728
Adv Dent Res. 2014 May;26(1):47-55
pubmed: 24736704
Ann Oncol. 2016 Aug;27(8):1619-25
pubmed: 27234641
Clin Oral Investig. 2019 Jan;23(1):179-185
pubmed: 29574499
Acta Otolaryngol. 2018 May;138(5):513-518
pubmed: 29161981
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Lancet. 2007 Jan 6;369(9555):51-9
pubmed: 17208642
Braz J Otorhinolaryngol. 2008 Jul-Aug;74(4):596-600
pubmed: 18852988
Pharmacol Res. 2013 Mar;69(1):137-43
pubmed: 23201354
Oral Microbiol Immunol. 2005 Dec;20(6):354-61
pubmed: 16238595
Biomed Rep. 2021 May;14(5):40
pubmed: 33728046
Cancer Prev Res (Phila). 2013 Sep;6(9):917-24
pubmed: 23966202
Acta Otolaryngol. 2005 Dec;125(12):1327-36
pubmed: 16303683
Br J Oral Maxillofac Surg. 2015 Nov;53(9):831-5
pubmed: 26388071
PLoS One. 2020 May 14;15(5):e0232871
pubmed: 32407339
Acta Otolaryngol. 2007 Sep;127(9):988-92
pubmed: 17712680
Oral Oncol. 2009 Apr-May;45(4-5):317-23
pubmed: 18674954
J Clin Oncol. 2008 Feb 1;26(4):612-9
pubmed: 18235120
Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2406-12
pubmed: 19745222
Braz Dent J. 2016 May-Jun;27(3):261-6
pubmed: 27224557
Periodontol 2000. 2002;29:104-21
pubmed: 12102705
Oral Oncol. 2001 Feb;37(2):153-8
pubmed: 11167142
Cancer Causes Control. 2014 Apr;25(4):461-71
pubmed: 24474236
J Periodontol. 2015 May;86(5):611-22
pubmed: 25688694
Oral Oncol. 2013 Oct;49(10):1010-7
pubmed: 23948049
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
Oral Oncol. 2017 May;68:92-102
pubmed: 28438300
Endoscopy. 2009 Mar;41(3):187-93
pubmed: 19280529
Head Neck Pathol. 2012 Jul;6 Suppl 1:S16-24
pubmed: 22782220
J Oral Pathol Med. 2014 Feb;43(2):137-42
pubmed: 24118314
Carcinogenesis. 2000 Apr;21(4):663-8
pubmed: 10753201
Periodontol 2000. 2012 Feb;58(1):10-25
pubmed: 22133364
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Prev Med. 2021 Mar;144:106445
pubmed: 33678237
J Periodontol. 2005 Mar;76(3):406-10
pubmed: 15857075
CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21
pubmed: 26215712
Oral Oncol. 2010 Jun;46(6):411-3
pubmed: 20381409

Auteurs

Lauri Jouhi (L)

Department of Otolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Jenna Sikiö (J)

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Anni Suomalainen (A)

Medical Imaging Center, Oral Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Rayan Mroueh (R)

Department of Otolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Antti Mäkitie (A)

Department of Otolaryngology, Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Department of Clinical Sciences, Division of Ear, Nose and Throat Diseases, Intervention and Technology, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden.

Jukka H Meurman (JH)

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH